The once-weekly oral combination of islatravir and lenacapavir maintained a similarly high rate of virologic suppression as standard daily oral therapy in an open-label phase II study[4][7]. The study evaluated the maintenance of virologic suppression up to week 24, and results showed maintenance of suppression in patients treated once weekly[4]. The combination included islatravir (a nucleoside reverse transcriptase inhibitor) and lenacapavir (an HIV-1 capsid inhibitor), with lenacapavir being approved as a long-acting capsid inhibitor and being investigated in various dosage forms[3][4]. The submitted data have been reported by the pharmaceutical companies Gilead and Merck and presented at professional conferences[4][9]. No new safety signals stood out significantly at this stage of the study according to the available reports[4][9]. These results support the further development of a weekly oral regimen as a potential alternative to daily tablets and long-acting injections, with further phases of investigation required for definitive conclusions[4][7].